The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints.

Neumann, Jennifer

The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints. [electronic resource] - International journal of cancer Apr 2014 - 1991-2002 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1097-0215

10.1002/ijc.28521 doi


Antineoplastic Agents--pharmacology
Ataxia Telangiectasia Mutated Proteins--drug effects
Benzofurans--pharmacology
Cell Line, Tumor
Cell Proliferation--drug effects
Checkpoint Kinase 1
Checkpoint Kinase 2--genetics
DNA Damage--drug effects
HCT116 Cells
HT29 Cells
Hep G2 Cells
Humans
Jurkat Cells
Leukemia--drug therapy
MCF-7 Cells
Phosphorylation--drug effects
Plant Extracts--pharmacology
Protein Biosynthesis--drug effects
Protein Kinases--genetics
RNA Interference
RNA, Small Interfering
S Phase Cell Cycle Checkpoints--drug effects
T-Lymphocytes--drug effects
cdc25 Phosphatases--biosynthesis